1. Signaling Pathways
  2. PI3K/Akt/mTOR
  3. Akt
  4. Akt1 Isoform
  5. Akt1 Inhibitor

Akt1 Inhibitor

Akt1 Inhibitors (5):

Cat. No. Product Name Effect Purity
  • HY-133120A
    INY-03-041 trihydrochloride
    Inhibitor 99.27%
    INY-03-041 trihydrochloride is a potent, highly selective and PROTAC-based pan-AKT degrader consisting of the ATP-competitive AKT inhibitor Ipatasertib (HY-15186) conjugated to Lenalidomide (HY-A0003, Cereblon ligand). INY-03-041 trihydrochloride inhibits AKT1, AKT2 and AKT3 with IC50s of 2.0, 6.8 and 3.5 nM, respectively.
  • HY-148868A
    Akt1&PKA-IN-2
    Inhibitor
    Akt1&PKA-IN-2 ((R)-29) is an inhibitor of PKB/AKT with cyclin-dependent kinase 2 (CDK2) selectivity. Akt1&PKA-IN-2 inhibits AKT1, PKAa and CDK2a with IC50 values of 0.007 µM, 0.01 µM and 0.69 µM, respectively.
  • HY-108232
    MK-2206
    Inhibitor
    MK-2206 is an orally active, highly potent and selective allosteric Akt inhibitor, with IC50s of 8, 12, and 65 nM for Akt1, Akt2, and Akt3, respectively. Many breast cancer cell lines, and PIK3CA-mutant and cell lines with PTEN loss are sensitive to MK-2206. MK-2206 has anticancer activities.
  • HY-129119
    Akt1/Akt2-IN-2
    Inhibitor
    Akt1/Akt2-IN-2 (compound 7) is an allosteric dual Akt1 and Akt2 inhibitor (IC50=138 nM and 212 nM, respectively). Akt1/Akt2-IN-2 increases activity of caspase-3, and inhibits viability of a number of tumor cells.
  • HY-16032
    Akt1-IN-2
    Inhibitor
    AKT-I-1 is a selective inhibitor of Akt1, with an IC50 of 4.6 µM.